Novocure Limited (NVCR)
Stock Price:
$75.79 USD
-0.38 (-0.50%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
After-hours: $76.12 +0.33 (0.44%) Jul 31, 7:56 PM
Key Info
| Market Cap |
7.66B |
| Revenue (ttm) |
409.05M |
| Net Income (ttm) |
11.80M |
| Shares Out |
100.44M |
| EPS (ttm) |
0.11 |
| PE Ratio |
689.00 |
| Forward PE |
123.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 31, 2020 |
| Last Price |
$75.79 |
| Previous Close |
$76.17 |
| Change ($) |
-0.38 |
| Change (%) |
-0.50% |
| Day's Open |
76.97 |
| Day's Range |
74.08 - 77.26 |
| Day's Volume |
2,231,974 |
| 52-Week Range |
53.40 - 98.84 |
More Stats
| Market Cap |
7.66B |
| Enterprise Value |
7.48B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
100.44M |
| Float |
83.39M |
| EPS (basic) |
0.13 |
| EPS (diluted) |
0.11 |
| FCF / Share |
0.24 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.15% |
| FCF Yield |
0.32% |
| Payout Ratio |
n/a |
| Shares Short |
3.38M |
| Short Ratio |
2.42 |
| Short % of Float |
3.62% |
| Beta |
1.53 |
| PE Ratio |
689.00 |
| Forward PE |
123.46 |
| P/FCF Ratio |
314.30 |
| PS Ratio |
18.73 |
| PB Ratio |
31.62 |
| Revenue |
409.05M |
| Operating Income |
7.30M |
| Net Income |
11.80M |
| Free Cash Flow |
24.38M |
| Net Cash |
184.34M |
| Net Cash / Share |
1.82 |
| Gross Margin |
64.31% |
| Operating Margin |
1.78% |
| Profit Margin |
2.90% |
| FCF Margin |
5.96% |
| ROA |
1.02% |
| ROE |
5.53% |
| ROIC |
1.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
4 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$82.43*
(8.76% upside)
Low
73.0
Current: $75.79
High
93.0
Target: 82.43
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 351 | 248 | 177 | 82.89 | 33.09 | 15.49 | 10.36 |
| Revenue Growth | 41.62% | 40.13% | 113.57% | 150.52% | 113.6% | 49.53% | - |
| Gross Profit | 263 | 168 | 121 | 36.61 | 12.48 | 5.45 | 3.35 |
| Operating Income | -0.91 | -33.67 | -39.33 | -115 | -104 | -80.16 | -64.46 |
| Net Income | -7.23 | -63.56 | -61.66 | -132 | -112 | -80.68 | -77.37 |
| Shares Outstanding | 97.24 | 91.83 | 88.55 | 85.56 | 30.40 | 12.49 | 11.50 |
| Earnings Per Share | -0.07 | -0.69 | -0.70 | -1.54 | -3.67 | -6.46 | -6.73 |
| Operating Cash Flow | 26.62 | -1.87 | -33.13 | -108 | -99.88 | -74.24 | -52.72 |
| Capital Expenditures | -10.49 | -6.71 | -7.37 | -17.66 | -10.27 | -2.32 | -3.63 |
| Free Cash Flow | 16.14 | -8.58 | -40.50 | -125 | -110 | -76.56 | -56.34 |
| Cash & Equivalents | 328 | 248 | 185 | 220 | 270 | 103 | 177 |
| Total Debt | 164 | 149 | 97.34 | 96.23 | 23.10 | - | - |
| Net Cash / Debt | 165 | 98.74 | 88.10 | 124 | 246 | 103 | 177 |
| Assets | 479 | 340 | 265 | 282 | 307 | 118 | 189 |
| Liabilities | 262 | 228 | 152 | 140 | 56.52 | 20.00 | 17.13 |
| Book Value | 218 | 112 | 114 | 142 | 251 | 97.88 | 172 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Novocure Limited |
| Country |
United Kingdom |
| Employees |
782 |
| CEO |
Asaf Danziger |
Stock Information
| Ticker Symbol |
NVCR |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: NVCR |
| IPO Date |
October 2, 2015 |
Description
NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.